QQQ   308.18 (+0.72%)
AAPL   158.64 (+0.79%)
MSFT   271.07 (-0.43%)
META   200.12 (+1.17%)
GOOGL   104.62 (+3.36%)
AMZN   99.81 (+2.15%)
TSLA   195.41 (+6.64%)
NVDA   261.65 (+1.02%)
NIO   9.29 (+6.17%)
BABA   83.32 (+2.86%)
AMD   95.87 (-0.97%)
T   18.46 (-0.16%)
F   11.68 (+4.47%)
MU   58.18 (+0.94%)
CGC   1.98 (+6.45%)
GE   92.50 (+2.87%)
DIS   96.12 (+2.02%)
AMC   4.38 (+2.58%)
PFE   40.36 (-1.10%)
PYPL   75.79 (+3.52%)
NFLX   304.31 (-0.27%)
QQQ   308.18 (+0.72%)
AAPL   158.64 (+0.79%)
MSFT   271.07 (-0.43%)
META   200.12 (+1.17%)
GOOGL   104.62 (+3.36%)
AMZN   99.81 (+2.15%)
TSLA   195.41 (+6.64%)
NVDA   261.65 (+1.02%)
NIO   9.29 (+6.17%)
BABA   83.32 (+2.86%)
AMD   95.87 (-0.97%)
T   18.46 (-0.16%)
F   11.68 (+4.47%)
MU   58.18 (+0.94%)
CGC   1.98 (+6.45%)
GE   92.50 (+2.87%)
DIS   96.12 (+2.02%)
AMC   4.38 (+2.58%)
PFE   40.36 (-1.10%)
PYPL   75.79 (+3.52%)
NFLX   304.31 (-0.27%)
QQQ   308.18 (+0.72%)
AAPL   158.64 (+0.79%)
MSFT   271.07 (-0.43%)
META   200.12 (+1.17%)
GOOGL   104.62 (+3.36%)
AMZN   99.81 (+2.15%)
TSLA   195.41 (+6.64%)
NVDA   261.65 (+1.02%)
NIO   9.29 (+6.17%)
BABA   83.32 (+2.86%)
AMD   95.87 (-0.97%)
T   18.46 (-0.16%)
F   11.68 (+4.47%)
MU   58.18 (+0.94%)
CGC   1.98 (+6.45%)
GE   92.50 (+2.87%)
DIS   96.12 (+2.02%)
AMC   4.38 (+2.58%)
PFE   40.36 (-1.10%)
PYPL   75.79 (+3.52%)
NFLX   304.31 (-0.27%)
QQQ   308.18 (+0.72%)
AAPL   158.64 (+0.79%)
MSFT   271.07 (-0.43%)
META   200.12 (+1.17%)
GOOGL   104.62 (+3.36%)
AMZN   99.81 (+2.15%)
TSLA   195.41 (+6.64%)
NVDA   261.65 (+1.02%)
NIO   9.29 (+6.17%)
BABA   83.32 (+2.86%)
AMD   95.87 (-0.97%)
T   18.46 (-0.16%)
F   11.68 (+4.47%)
MU   58.18 (+0.94%)
CGC   1.98 (+6.45%)
GE   92.50 (+2.87%)
DIS   96.12 (+2.02%)
AMC   4.38 (+2.58%)
PFE   40.36 (-1.10%)
PYPL   75.79 (+3.52%)
NFLX   304.31 (-0.27%)
NASDAQ:CLNN

Clene - CLNN Stock Forecast, Price & News

$1.20
+0.02 (+1.35%)
(As of 03/21/2023 01:52 PM ET)
Add
Compare
Today's Range
$1.17
$1.20
50-Day Range
$1.07
$1.62
52-Week Range
$0.87
$5.13
Volume
94,730 shs
Average Volume
1.20 million shs
Market Capitalization
$92.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33

Clene MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
855.6% Upside
$11.43 Price Target
Short Interest
Healthy
6.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Clene in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.46) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

308th out of 988 stocks

Pharmaceutical Preparations Industry

134th out of 482 stocks


CLNN stock logo

About Clene (NASDAQ:CLNN) Stock

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Receive CLNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter.

CLNN Stock News Headlines

Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Clene Appoints Neurology Expert to Executive Team
Clene (NASDAQ:CLNN) Stock Rating Reaffirmed by HC Wainwright
Clene (NASDAQ:CLNN) PT Raised to $8.00
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Clene (NASDAQ:CLNN) Now Covered by EF Hutton Acquisition Co. I
See More Headlines
Receive CLNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter.

CLNN Company Calendar

Last Earnings
11/08/2021
Today
3/21/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLNN
Fax
N/A
Employees
95
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.43
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+860.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-29,920,000.00
Net Margins
-6,325.16%
Pretax Margin
-6,325.16%

Debt

Sales & Book Value

Annual Sales
$470,000.00
Book Value
$0.04 per share

Miscellaneous

Free Float
54,850,000
Market Cap
$90.78 million
Optionable
Not Optionable
Beta
0.39

Key Executives

  • Mr. Robert Etherington MBA (Age 55)
    CEO, Pres & Director
    Comp: $820.13k
  • Mr. Mark G. Mortenson (Age 64)
    Co-Founder & Chief Science Officer
    Comp: $628.43k
  • Dr. Robert Glanzman M.D. (Age 65)
    Chief Medical Officer
    Comp: $573.39k
  • Mr. Morgan R. Brown CPA (Age 54)
    CPA, M.B.A., MBA, Chief Financial Officer
  • Mr. Jerry Miraglia J.D.
    Gen. Counsel & Corp. Sec.
  • Mr. Michael T. Hotchkin
    Chief Devel. Officer
  • Ms. Mary Anne Mcneil
    Head of HR
  • Dr. Tae Heum Jeong D. Mgt. (Age 51)
    Consultant













CLNN Stock - Frequently Asked Questions

Should I buy or sell Clene stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clene in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLNN shares.
View CLNN analyst ratings
or view top-rated stocks.

What is Clene's stock price forecast for 2023?

7 brokers have issued 1 year price objectives for Clene's shares. Their CLNN share price forecasts range from $6.00 to $17.00. On average, they predict the company's stock price to reach $11.43 in the next twelve months. This suggests a possible upside of 868.5% from the stock's current price.
View analysts price targets for CLNN
or view top-rated stocks among Wall Street analysts.

How have CLNN shares performed in 2023?

Clene's stock was trading at $1.00 at the beginning of the year. Since then, CLNN shares have increased by 18.0% and is now trading at $1.18.
View the best growth stocks for 2023 here
.

Are investors shorting Clene?

Clene saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 1,870,000 shares, a drop of 37.9% from the February 13th total of 3,010,000 shares. Based on an average daily trading volume, of 926,400 shares, the short-interest ratio is presently 2.0 days. Approximately 6.7% of the company's stock are short sold.
View Clene's Short Interest
.

When is Clene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our CLNN earnings forecast
.

How were Clene's earnings last quarter?

Clene Inc. (NASDAQ:CLNN) issued its quarterly earnings results on Monday, November, 8th. The company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.62. The firm earned $0.11 million during the quarter, compared to the consensus estimate of $0.14 million. Clene had a negative trailing twelve-month return on equity of 4,043.36% and a negative net margin of 6,325.16%.

What is Clene's stock symbol?

Clene trades on the NASDAQ under the ticker symbol "CLNN."

Who are Clene's major shareholders?

Clene's stock is owned by many different institutional and retail investors. Top institutional shareholders include Kepos Capital LP (0.47%), Susquehanna International Group LLP (0.00%), Geode Capital Management LLC (0.31%), Simplex Trading LLC (0.00%), Atom Investors LP (0.17%) and Millennium Management LLC (0.16%). Insiders that own company stock include Alison Mosca, David J Matlin, David J Matlin, General Resonance Llc, John Henry Stevens, Jonathon Gay, Robert Dee Etherington and Robert Glanzman.
View institutional ownership trends
.

How do I buy shares of Clene?

Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clene's stock price today?

One share of CLNN stock can currently be purchased for approximately $1.18.

How much money does Clene make?

Clene (NASDAQ:CLNN) has a market capitalization of $90.78 million and generates $470,000.00 in revenue each year. The company earns $-29,920,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

How can I contact Clene?

Clene's mailing address is UNIT 902 9/F LUCKY BUILDING 39 WELLINGTON STREET, HONG KONG K3, . The official website for the company is clene.com. The company can be reached via phone at 801-676-9695 or via email at ir@clene.com.

This page (NASDAQ:CLNN) was last updated on 3/21/2023 by MarketBeat.com Staff